Document Type : Research Articles
Authors
1
Department of Oncology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, China.
2
Faculty of Medicine, MAHSA University, Jenjarom 42610, Selangor, Malaysia.
3
Youjiang Medical University for Nationalities, Baise, 533000, China.
4
Department of Preclinical Sciences, Faculty of Dentistry, MAHSA University, Jenjarom 42610, Selangor, Malaysia.
5
College of Medical Technology, Guiyang Healthcare Vocational University, Guiyang 550081, China.
Abstract
Objective: This study preliminarily examines the clinical value and molecular mechanisms of LINC00511 in breast cancer (BRCA) through bioinformatics analysis. Methods: Expression data of LINC00511 and related information for BRCA samples were collected from the TCGA website. The levels of LINC00511 in cancerous and normal tissues were compared using the Wilcoxon rank-sum test. The relationship between LINC00511 levels and clinicopathological features was examined using the chi-square test. Additionally, Kaplan-Meier and Cox regression analyses were employed to evaluate the prognostic significance of LINC00511. Finally, to determine the biological functions and molecular mechanisms of LINC00511, functional enrichment and immune infiltration analyses were performed using the Xiantao Academic website. Results: LINC00511 was found to be upregulated in BRCA. LINC00511 expression was closely related to T stage, pathological stage, race, estrogen receptor (ER), and progesterone receptor (PR). For BRCA patients, independent prognostic factors included older age (≥65 years), advanced pathological stages (III and IV), and elevated LINC00511 levels. Enrichment analysis demonstrated the close association of LINC00511 with the IL-17 signaling pathway, estrogen signaling pathway, chemical carcinogenesis, and drug metabolism. Furthermore, LINC00511 expression was significantly related to the level of immune cell infiltration. Conclusion: LINC00511 is significantly overexpressed in BRCA, and elevated levels of this factor are associated with a reduction in overall survival in BRCA patients. LINC00511 not only possesses a high degree of clinical value in the diagnosis and prognosis of BRCA but also has the potential to serve as a target for immunotherapy.
Keywords
Main Subjects
)